Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.
about
Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-AnalysisOptimization of cardiac metabolism in heart failureTargeting myocardial substrate metabolism in heart failure: potential for new therapiesIs treatment with trimetazidine beneficial in patients with chronic heart failure?Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammationModulating fatty acid oxidation in heart failure.Structure dependence of long-chain [18F]fluorothia fatty acids as myocardial fatty acid oxidation probes.Emerging drugs for acute and chronic heart failure: current and future developments.A "PET" area of interest: myocardial metabolism in human systolic heart failure.Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.Metabolic modulation and cellular therapy of cardiac dysfunction and failure.Potential of metabolic agents as adjunct therapies in heart failure.Metabolic remodelling in human heart failure.Efficacy of metabolic modulators in ischemic heart disease: an overview.Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials.Cardiac metabolism in hypertrophy and heart failure: implications for therapy.Trimetazidine and cardioprotection: facts and perspectives.Carvedilol in chronic heart failure: past, present and future.Metabolic manipulation in dilated cardiomyopathy: Assessing the role of trimetazidine.Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy - Six months follow-up result.Myocardial metabolic manipulation: a new therapeutic approach in heart failure?Trimetazidine shortens QTc interval in patients with ischemic heart failure.Trimetazidine: the future of cardiac function?Metabolic Modulation of Cardiac Metabolism in Heart Failure
P2860
Q26787236-AFA9244D-68BD-49A4-B912-280721021759Q27023021-B617B377-39CB-434C-9041-CEF4A3BA6AF9Q27694733-CE4137CE-63FA-4D61-A42B-FB0B0661E475Q33567682-3333DEB7-73C7-45E4-9B0B-BD25F5E87AD4Q34336231-E2DC7B14-338D-4B89-9BF3-10715B19B409Q34808505-096562AC-140A-456C-A534-E525BB88BA00Q36497055-0A3406EE-5DA3-4C8B-9B73-CBEA329874E1Q36758585-6723E746-4D31-4526-A955-272A5131ED3FQ37086847-F87A9613-0DB3-46C9-820B-F588B941DFF5Q37165686-409C04EA-1267-43F7-A688-AF5831E08012Q37296154-5A8D498A-5559-45CB-80E4-0E6D520A400DQ37608595-D1FDB8D7-5A5D-40D3-9E87-B5A0C66B75A1Q37849446-676E0206-538A-4C45-AA19-01C95E9C0358Q37850633-29EBE790-E3F3-45BF-A28D-F023C9E2CE78Q37871496-18CEFB82-89C2-4E87-AC9C-9FAA5289FC7CQ38057699-2F8167F6-632F-410E-8AD0-0F44C46E794EQ38203492-82962329-4526-40DC-8533-E7B6A5FB741EQ40377169-B6A96366-6D1A-41B9-8B7F-39DB4DFF4811Q42837504-0EFDF35E-457D-4809-81AA-C83DB6B9AD72Q42837522-B79C1E20-7500-49BE-9693-52B7AF5A1EF7Q43012953-AFC06F4E-D429-43BC-AB05-62F8707DC308Q43228705-34EE3E5A-15C3-46E0-AB48-3EE76C587E5FQ43284147-AF5355D5-41AA-4852-BB2A-53290B950C77Q58804689-131C280D-8ED1-4AC0-A7B7-B744DC1B960E
P2860
Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Long term cardioprotective act ...... haemic dilated cardiomyopathy.
@ast
Long term cardioprotective act ...... haemic dilated cardiomyopathy.
@en
type
label
Long term cardioprotective act ...... haemic dilated cardiomyopathy.
@ast
Long term cardioprotective act ...... haemic dilated cardiomyopathy.
@en
prefLabel
Long term cardioprotective act ...... haemic dilated cardiomyopathy.
@ast
Long term cardioprotective act ...... haemic dilated cardiomyopathy.
@en
P2093
P2860
P356
P1433
P1476
Long term cardioprotective act ...... haemic dilated cardiomyopathy.
@en
P2093
A A Taccardi
A Barsotti
P Di Napoli
P2860
P304
P356
10.1136/HRT.2003.031310
P407
P577
2005-02-01T00:00:00Z